Qianjiang Yongan Pharmaceutical Co Ltd Total Liabilities
Qianjiang Yongan Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Qianjiang Yongan Pharmaceutical Co Ltd (002365) has total liabilities worth CN¥247.20 Million CNY (≈ $36.17 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Qianjiang Yongan Pharmaceutical Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Qianjiang Yongan Pharmaceutical Co Ltd (2006–2024)
Total liabilities of Qianjiang Yongan Pharmaceutical Co Ltd from 2006 to 2024. This chart illustrates how Qianjiang Yongan Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 002365 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Qianjiang Yongan Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Qianjiang Yongan Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SD Biosensor Inc
KO:137310
|
Korea | ₩495.94 Billion |
|
Potbelly Co
NASDAQ:PBPB
|
USA | $204.14 Million |
|
W&T Offshore Inc
NYSE:WTI
|
USA | $1.16 Billion |
|
Shanghai Baosight Software Co Ltd B
SHG:900926
|
China | $10.57 Billion |
|
Zhongjin Irradiation Incorporated Company
SHE:300962
|
China | CN¥481.47 Million |
|
Grenevia S.A.
WAR:GEA
|
Poland | zł1.79 Billion |
|
Shanghai Golden Bridge
SHG:603918
|
China | CN¥319.78 Million |
|
Savita Oil Technologies Limited
NSE:SOTL
|
India | Rs8.98 Billion |
Liability Composition Analysis (2006–2024)
This chart breaks down Qianjiang Yongan Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Qianjiang Yongan Pharmaceutical Co Ltd.
Liquidity & Leverage Metrics
Qianjiang Yongan Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Qianjiang Yongan Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Qianjiang Yongan Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Qianjiang Yongan Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual total liabilities of Qianjiang Yongan Pharmaceutical Co Ltd from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥266.55 Million ≈ $39.00 Million |
-10.81% |
| 2023-12-31 | CN¥298.85 Million ≈ $43.73 Million |
-6.95% |
| 2022-12-31 | CN¥321.17 Million ≈ $47.00 Million |
-2.36% |
| 2021-12-31 | CN¥328.95 Million ≈ $48.14 Million |
-6.00% |
| 2020-12-31 | CN¥349.92 Million ≈ $51.21 Million |
+39.34% |
| 2019-12-31 | CN¥251.14 Million ≈ $36.75 Million |
-22.28% |
| 2018-12-31 | CN¥323.11 Million ≈ $47.28 Million |
+37.36% |
| 2017-12-31 | CN¥235.23 Million ≈ $34.42 Million |
+144.48% |
| 2016-12-31 | CN¥96.22 Million ≈ $14.08 Million |
+15.24% |
| 2015-12-31 | CN¥83.50 Million ≈ $12.22 Million |
+5.50% |
| 2014-12-31 | CN¥79.14 Million ≈ $11.58 Million |
-35.40% |
| 2013-12-31 | CN¥122.50 Million ≈ $17.93 Million |
+5.08% |
| 2012-12-31 | CN¥116.59 Million ≈ $17.06 Million |
+11.96% |
| 2011-12-31 | CN¥104.13 Million ≈ $15.24 Million |
+36.76% |
| 2010-12-31 | CN¥76.14 Million ≈ $11.14 Million |
+9.04% |
| 2009-12-31 | CN¥69.83 Million ≈ $10.22 Million |
-41.83% |
| 2008-12-31 | CN¥120.04 Million ≈ $17.57 Million |
+90.88% |
| 2007-12-31 | CN¥62.89 Million ≈ $9.20 Million |
+35.99% |
| 2006-12-31 | CN¥46.24 Million ≈ $6.77 Million |
-- |
About Qianjiang Yongan Pharmaceutical Co Ltd
Qianjiang Yongan Pharmaceutical Co., Ltd. engages in production and sale of taurine in China. It produces ethylene oxide, polycarboxylic acid-based water reducer monomers, water reducers, and health products. The company engages in scientific research and technical service, creatine monohydrate, wholesale and retail trade, leasing and business services, and crop farming. Qianjiang Yongan Pharmace… Read more